Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor in Maintenance Therapy for p53 Wild-Type Endometrial Carcinoma
NCT05611931Phase 3Active, not recruiting
- Sponsor
- Karyopharm Therapeutics Inc.
- Start
- Apr 2023
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 17
01
Overview
Phase 3, randomised, double-blind trial in endometrial carcinoma comparing Selinexor with Placebo (2 arms). Primary endpoint: Progression Free Survival up to 34 months. Started Apr 2023; status: active, not recruiting.
02
Drugs
selinexor
03
Conditions
endometrial carcinoma
Beyond the preview
Go deeper on NCT05611931.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05611931.